Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Forxiga (Dapagliflozin) Regulatory Post Marketing Surveillance

NCT07210307 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07210307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07210307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Forxiga (Dapagliflozin) Regulatory Post Marketing Surveillance
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
October 31, 2017
Completion date
March 17, 2020
Enrollment
1,001 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

safety outcomes